US20080085897A1 - Use of 2-alkoxyphenyl-substituted imidazotriazinones - Google Patents
Use of 2-alkoxyphenyl-substituted imidazotriazinones Download PDFInfo
- Publication number
- US20080085897A1 US20080085897A1 US11/906,382 US90638207A US2008085897A1 US 20080085897 A1 US20080085897 A1 US 20080085897A1 US 90638207 A US90638207 A US 90638207A US 2008085897 A1 US2008085897 A1 US 2008085897A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- triazin
- propyl
- imidazo
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1=NC([1*])=C2C(=O)NC(C3=CC=CC=C3)=NN12.CSO(C)O.[16*]C Chemical compound *C1=NC([1*])=C2C(=O)NC(C3=CC=CC=C3)=NN12.CSO(C)O.[16*]C 0.000 description 7
- SECKRCOLJRRGGV-UHFFFAOYSA-N CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(CC)CC4)=C3)=NN12 Chemical compound CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(CC)CC4)=C3)=NN12 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 6
- ZHNKUVIYUVHPHO-UHFFFAOYSA-N CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N(CC)CC)=C3)=NN12 Chemical compound CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N(CC)CC)=C3)=NN12 ZHNKUVIYUVHPHO-UHFFFAOYSA-N 0.000 description 2
- ZJTVHYFMYGFDEM-UHFFFAOYSA-M [Cl-].[H]N1(CC)CCN(S(=O)(=O)C2=CC(C3=NN4C(CCC)=NC(C)=C4C(=O)N3)=C(OCC)C=C2)CC1 Chemical compound [Cl-].[H]N1(CC)CCN(S(=O)(=O)C2=CC(C3=NN4C(CCC)=NC(C)=C4C(=O)N3)=C(OCC)C=C2)CC1 ZJTVHYFMYGFDEM-UHFFFAOYSA-M 0.000 description 2
- LJCDJCJZDSILFJ-UHFFFAOYSA-N CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N(CCC)CCO)=C3)=NN12 Chemical compound CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N(CCC)CCO)=C3)=NN12 LJCDJCJZDSILFJ-UHFFFAOYSA-N 0.000 description 1
- NBHHJPXTDGACKT-UHFFFAOYSA-N CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCC(O)CC4)=C3)=NN12 Chemical compound CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCC(O)CC4)=C3)=NN12 NBHHJPXTDGACKT-UHFFFAOYSA-N 0.000 description 1
- AIVNVMRJLJHFCU-UHFFFAOYSA-N CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(C)CC4)=C3)=NN12 Chemical compound CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(C)CC4)=C3)=NN12 AIVNVMRJLJHFCU-UHFFFAOYSA-N 0.000 description 1
- CRBBKMLCEYBSDP-UHFFFAOYSA-N CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(C5CCCC5)CC4)=C3)=NN12 Chemical compound CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(C5CCCC5)CC4)=C3)=NN12 CRBBKMLCEYBSDP-UHFFFAOYSA-N 0.000 description 1
- KZFHUILKKFVOMB-UHFFFAOYSA-N CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(CCO)CC4)=C3)=NN12 Chemical compound CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(CCO)CC4)=C3)=NN12 KZFHUILKKFVOMB-UHFFFAOYSA-N 0.000 description 1
- JIABABMNCJOIBE-UHFFFAOYSA-N CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCOCC4)=C3)=NN12 Chemical compound CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCOCC4)=C3)=NN12 JIABABMNCJOIBE-UHFFFAOYSA-N 0.000 description 1
- HWGDUCPPRLACNS-UHFFFAOYSA-N CCCC1=NC(CC)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(CC)CC4)=C3)=NN12 Chemical compound CCCC1=NC(CC)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(CC)CC4)=C3)=NN12 HWGDUCPPRLACNS-UHFFFAOYSA-N 0.000 description 1
- ZLOXKBYVNBOBAO-UHFFFAOYSA-N CCCc1nc(CC)c2[n]1N=C(c1cc(S(N3CCN(C)CC3)(=O)=O)ccc1OCC)NC2=O Chemical compound CCCc1nc(CC)c2[n]1N=C(c1cc(S(N3CCN(C)CC3)(=O)=O)ccc1OCC)NC2=O ZLOXKBYVNBOBAO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to the use of 2-alkoxyphenyl-substituted imidazo-triazinones for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
- ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
- FR 22 13 058, CH 59 46 71, DE 22 55 172, DE 23 64 076 and EP 000 9384 describe imidazotriazinones which have no substituted aryl radical in the 2-position, and are likewise described as bronchodilators having cAMP PDE-inhibitory action.
- WO 94/28902 describes pyrazolopyrimidinones which are suitable for the treatment of impotence.
- WO 99/24433 and WO 99/67244 describe imidazotriazinones which are suitable for the treatment of impotence.
- phosphodiesterases having differing specificity against the cyclic nucleotides cAMP and cGMP are described in the literature (cf. Fawcett et al., Proc. Nat. Acad. Sci. 97(7), 3072-3077 (2000).
- Cyclic guanosine 3′,5′-monophosphate-metabolizing phosphodiesterases (cGMP PDEs) are PDE-1, 2, 5, 6, 9, 10, 11.
- the compounds according to the invention are potent inhibitors of phosphodiesterase 5.
- This is particularly to be expected if the synthesis of cGMP is increased under certain physiological conditions. For example, during sexual stimulation by the neuronal pathway, nitrogen monoxide is released in the vessels of the corpus cavemosum and thus the synthesis of cGMP is increased. This leads to a strong dilation of the vessels which supply the corpus cavemosum with blood, and thus to erection.
- Inhibitors of cGMP-metabolizing PDEs should therefore be particularly suitable for the treatment of erectile dysfunction.
- An increase in the cGMP concentration can lead to curative, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilating, natriuretic and diuretic effects and can influence the conduction in the central nervous system and thus the memory power. It can influence the short- or long-term modulation of the vascular and cardiac inotropy, the heart rhythm and the cardiac conduction (J. C. Stoclet, T. Keravis, N. Komas and C. Lugnier, Exp. Opin. Invest. Drugs (1995), 4 (11), 1081-1100).
- the present invention relates to the use of compounds of the general formula (I) in which
- physiologically acceptable salts are preferred.
- Physiologically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids.
- Preferred salts are those with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid, or salts with organic carboxylic or sulphonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulphonic acid, ethanesulphonic acid, phenylsulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid.
- Physiologically acceptable salts can likewise be metal or ammonium salts of the compounds according to the invention.
- Those particularly preferred are, for example, sodium, potassium, magnesium or calcium salts, and ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine.
- the compounds according to the invention can also be present as hydrates.
- hydrates are understood as meaning those compounds which contain water in the crystal.
- Such compounds can contain one or more, typically 1 to 5, equivalents of water.
- Hydrates can be prepared, for example, by crystallizing the compound concerned from water or a water-containing solvent.
- Solvates of the compounds according to the invention are stoichiometric compositions of the compounds or their salts with solvents.
- acyl radical having 1 to 3 carbon atoms in the context of the invention represents, for example, formyl, acetyl or ethylcarbonyl.
- a straight-chain or branched alkoxy radical having 1 to 3 carbon atoms in the context of the invention represents methoxy, ethoxy, n-propoxy, or isopropoxy.
- alkoxycarbonyl radical having 1 to 3 carbon atoms in the context of the invention represents methoxycarbonyl or ethoxycarbonyl.
- a straight-chain or branched alkyl radical having 1 to 5 or 1 to 3 carbon atoms in the context of the invention represents, for example, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl.
- Straight-chain or branched alkyl radicals having 1 to 4 or 1 to 3 carbon atoms are preferred.
- Halogen in the context of the invention in general represents fluorine, chlorine, bromine or iodine. Fluorine, chlorine and bromine are preferred. Fluorine and chlorine are particularly preferred.
- a further embodiment of the invention relates to the use according to the invention of compounds of the general formula (I), in which the radicals R 16 and —SO 2 NR 3 R 4 are in the para-position to one another on the phenyl ring and R 1 , R 2 , R 3 , R 4 and R 16 have the meaning indicated above.
- a further embodiment of the invention relates to the use according to the invention of compounds of the general formula (Ia), where R 1 , R 2 , R 3 , R 4 and R 16 have the meaning indicated above, and their salts, hydrates and/or solvates.
- the compounds according to the invention inhibit the c-GMP-metabolizing phosphodiesterases 5. This leads to an increase in c-GMP.
- the compounds according to the invention reinforce the action of substances, such as, for example, EDRF (endothelium derived relaxing factor), ANP (atrial natriuretic peptide), of nitro vasodilators and all other substances which increase the cGMP concentration in a manner other than phosphodiesterase inhibitors.
- substances such as, for example, EDRF (endothelium derived relaxing factor), ANP (atrial natriuretic peptide), of nitro vasodilators and all other substances which increase the cGMP concentration in a manner other than phosphodiesterase inhibitors.
- the compounds of the general formula (I) according to the invention are therefore suitable for the prophylaxis and/or treatment of disorders in which an increase in the cGMP concentration is beneficial, i.e. disorders which are connected with cGMP-regulated processes (in English usually simply designated as ‘cGMP-related diseases’).
- cardiac insufficiency psoriasis
- psoriasis female infertility
- cancer a malignant neoplasm
- diabetes ophthalmic disorders
- glaucoma disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
- ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
- Temporary or permanent damage to the eyes can result on account of constriction of a blood vessel and a defective supply of the eye with nutrients resulting therefrom.
- There are reports about a slowing of the progress of glaucomatous optical neuropathy in the case of systemic administration of an NO donor, which could be attributed to a dilation of the blood vessels in the eye cf. Afshari, Invest. Opthalmol. Vis. Sci.
- Inhibitors of the cGMP PDE lead—as described above—analogously to NO donors, to an increase in the cGMP level and can thus, inter alia, cause a vasodilation of the blood vessels in the eyes and thus be used for the treatment of glaucomas.
- the compounds of the formula (I), however, can also be used for the treatment of other disorders of the eye, for example for the treatment or prophylaxis of central retinal or posterior ciliary arterial occlusion, central retinal venous occlusion, optical neuropathy such as anterior ischaemic optical neuropathy and glaucomatous optical neuropathy, and of macular degeneration.
- the active compounds and their physiologically acceptable salts can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic pharmaceutically suitable vehicles or solvents.
- the therapeutically active compound should in each case be present here in a concentration of approximately 0.5 to 9% by weight of the total mixture, i.e. in amounts which are sufficient in order to achieve the dosage range indicated.
- the formulations are prepared, for example, by extending the active compounds using solvents and/or vehicles, optionally using emulsifying agents and/or dispersing agents, where, for example, if water is used as a diluent, organic solvents can optionally be used as auxiliary solvents.
- Administration is carried out in a customary manner, preferably orally, transdermally or parenterally, e.g. perlingually, buccally, intravenously, nasally, rectally or by inhalation.
- doses of 0.001 to 50 mg/kg, preferably 0.01 mg/kg-20 mg/kg are more usefully administered.
- parenteral administration such as, for example, nasally, buccally or by inhalation via the mucous membranes, a dose of 0.001 mg/kg-0.5 mg/kg is useful.
- the compounds according to the invention are also suitable for use in veterinary medicine.
- the compounds or their non-toxic salts are administered in a suitable formulation in agreement with the general veterinary medical practices.
- the veterinary surgeon can fix the type of administration and the dose according to the type of the animal to be treated.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the treatment of cardiac insufficiency, cancer, bladder disorders, or prostate hyperplasia.
Description
- This application is a continuation of application Ser. No. 11/156,082 filed Jun. 17, 2005, which was a divisional of application Ser. No. 10/483,462 filed Aug. 16, 2005, which was a 371 application of PCT/EP2002/07959 filed Jul. 17, 2002.
- The present invention relates to the use of 2-alkoxyphenyl-substituted imidazo-triazinones for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
- Offenlegungsschrift DE 28 11 780 describes imidazotriazinones as bronchodilators having spasmolytic activity and inhibitory activity against cyclic adenosine monophosphate metabolizing-phosphodiesterases (cAMP PDEs, nomenclature according to Beavo: PDE-III and PDE-IV). An inhibitory action against cyclic guanosine monophosphate-metabolizing phosphodiesterases (cGMP PDEs, nomenclature according to Beavo and Reifsnyder (Trends in Pharmacol. Sci. 11, 150-155, 1990) PDE-I, PDE-II and PDE-V) is not described. No compounds are claimed which contain a sulphonamide group in the aryl radical in the 2-position. Furthermore, FR 22 13 058, CH 59 46 71, DE 22 55 172, DE 23 64 076 and EP 000 9384 describe imidazotriazinones which have no substituted aryl radical in the 2-position, and are likewise described as bronchodilators having cAMP PDE-inhibitory action.
- WO 94/28902 describes pyrazolopyrimidinones which are suitable for the treatment of impotence.
- WO 99/24433 and WO 99/67244 describe imidazotriazinones which are suitable for the treatment of impotence.
- At present, 11 phosphodiesterases having differing specificity against the cyclic nucleotides cAMP and cGMP are described in the literature (cf. Fawcett et al., Proc. Nat. Acad. Sci. 97(7), 3072-3077 (2000). Cyclic guanosine 3′,5′-monophosphate-metabolizing phosphodiesterases (cGMP PDEs) are PDE-1, 2, 5, 6, 9, 10, 11. The compounds according to the invention are potent inhibitors of phosphodiesterase 5. The differential expression of the phosphodiesterases in various cells, tissues and organs, just like the differential subcellular location of these enzymes, make possible, in combination with the selective inhibitors according to the invention, a selective increase in the cGMP concentration in specific cells, tissues and organs and thereby make possible the addressing of various processes regulated by cGMP. This is particularly to be expected if the synthesis of cGMP is increased under certain physiological conditions. For example, during sexual stimulation by the neuronal pathway, nitrogen monoxide is released in the vessels of the corpus cavemosum and thus the synthesis of cGMP is increased. This leads to a strong dilation of the vessels which supply the corpus cavemosum with blood, and thus to erection. Inhibitors of cGMP-metabolizing PDEs should therefore be particularly suitable for the treatment of erectile dysfunction.
- An increase in the cGMP concentration can lead to curative, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilating, natriuretic and diuretic effects and can influence the conduction in the central nervous system and thus the memory power. It can influence the short- or long-term modulation of the vascular and cardiac inotropy, the heart rhythm and the cardiac conduction (J. C. Stoclet, T. Keravis, N. Komas and C. Lugnier, Exp. Opin. Invest. Drugs (1995), 4 (11), 1081-1100).
-
- R1 represents methyl or ethyl,
- R2 represents ethyl or propyl,
- R3 and R4 are identical or different and represent a straight-chain or branched alkyl chain having up to 5 carbon atoms, which is optionally up to disubstituted identically or differently by hydroxyl or methoxy,
- or
- R3 and R4 together with the nitrogen atom form a piperidinyl ring, morpholinyl ring, thiomorpholinyl ring or a radical of the formula
- in which
- R5 denotes hydrogen, formyl, acyl or alkoxycarbonyl in each case having up to 3 carbon atoms,
- or denotes straight-chain or branched alkyl having up to 3 carbon atoms, which is optionally mono- to disubstituted, identically or differently, by hydroxyl, carboxyl, straight-chain or branched alkoxy or alkoxycarbonyl in each case having up to 3 carbon atoms or by groups of the formula -(D)a-NR6R7 or —P(O)(OR8)(OR9),
- in which
- a denotes a number 0 or 1,
- D denotes a group of the formula —CO,
- R6 and R7 are identical or different and denote hydrogen or methyl,
- R8 and R9 are identical or different and denote hydrogen, methyl or ethyl,
- or
- R5 denotes cyclopentyl,
- and the heterocycles mentioned under R3 and R4, formed together with the nitrogen atom, are optionally mono- to disubstituted, identically or differently, optionally also geminally, by hydroxyl, formyl, carboxyl, acyl or alkoxycarbonyl in each case having up to 3 carbon atoms or groups of the formula —P(O)(OR10)(OR11) or —(CO)nNR12R13,
- in which
- R10 and R11 are identical or different and denote hydrogen, methyl or ethyl,
- b denotes a number 0 or 1,
- and
- R12 and R13 are identical or different and denote hydrogen or methyl
- and/or the heterocycles mentioned under R3 and R4, formed together with the nitrogen atom, are optionally substituted by straight-chain or branched alkyl having up to 3 carbon atoms, which is optionally mono- to disubstituted, identically or differently, by hydroxyl, carboxyl or by a radical of the formula P(O)OR14OR15,
- in which
- R14 and R15 are identical or different and denote hydrogen, methyl or ethyl,
- and/or the heterocycles mentioned under R3 and R4, formed together with the nitrogen atom, are optionally substituted by piperidinyl or pyrrolidinyl which is linked via N,
- and
- R16 represents ethoxy or propoxy,
and their salts, hydrates and/or solvates, for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
- The use of the following compounds is particularly preferred according to the present invention:
Structure
for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome. - In the context of the invention, physiologically acceptable salts are preferred. Physiologically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids. Preferred salts are those with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid, or salts with organic carboxylic or sulphonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulphonic acid, ethanesulphonic acid, phenylsulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid.
- Physiologically acceptable salts can likewise be metal or ammonium salts of the compounds according to the invention. Those particularly preferred are, for example, sodium, potassium, magnesium or calcium salts, and ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine.
- The compounds according to the invention, in particular the salts, can also be present as hydrates. In the context of the invention, hydrates are understood as meaning those compounds which contain water in the crystal. Such compounds can contain one or more, typically 1 to 5, equivalents of water. Hydrates can be prepared, for example, by crystallizing the compound concerned from water or a water-containing solvent.
- Solvates of the compounds according to the invention are stoichiometric compositions of the compounds or their salts with solvents.
- An acyl radical having 1 to 3 carbon atoms in the context of the invention represents, for example, formyl, acetyl or ethylcarbonyl.
- A straight-chain or branched alkoxy radical having 1 to 3 carbon atoms in the context of the invention represents methoxy, ethoxy, n-propoxy, or isopropoxy.
- An alkoxycarbonyl radical having 1 to 3 carbon atoms in the context of the invention represents methoxycarbonyl or ethoxycarbonyl.
- A straight-chain or branched alkyl radical having 1 to 5 or 1 to 3 carbon atoms in the context of the invention represents, for example, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl. Straight-chain or branched alkyl radicals having 1 to 4 or 1 to 3 carbon atoms are preferred.
- Halogen in the context of the invention in general represents fluorine, chlorine, bromine or iodine. Fluorine, chlorine and bromine are preferred. Fluorine and chlorine are particularly preferred.
- A further embodiment of the invention relates to the use according to the invention of compounds of the general formula (I), in which the radicals R16 and —SO2NR3R4 are in the para-position to one another on the phenyl ring and R1, R2, R3, R4 and R16 have the meaning indicated above.
-
- The use according to the invention of the following compounds is preferred:
- 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo-[5,1-f]-[1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-hydroxyethylpiperazine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo[5,1-f]-[1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-hydroxypiperidine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo-[5,1-f]-[1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-hydroxymethylpiperidine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(3-hydroxypyrrolidine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo[5,1-f]-[1,2,4]triazin-4-one;
- 4-ethoxy-N-ethyl-N-(2-hydroxyethyl)-3-(5,7-dimethyl-4-oxo-3,4-dihydro-imidazo-[5,1-f]-[1,2,4]triazin-2-yl)benzenesulphonamide;
- 5 N,N-diethyl-4-ethoxy-3-(5,7-dimethyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonamide;
- 2-[2-ethoxy-5-(4-(2-pyrimidinyl)-piperazine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo-[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(morpholin-4-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo[5,1-f]-[1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(1,4-dioxa-6-azaspiro[4.4]nonane-6-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- N,N-bis-(2-methoxyethyl)-4-ethoxy-3-(5,7-dimethyl-4-oxo-3,4-dihydroimidazo[5,1-f]-[1,2,4]triazin-2-yl)-benzenesulphonamide;
- N-(3-isoxazolyl)-4-ethoxy-3-(5,7-dimethyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonamide;
- 2-[2-ethoxy-5-(2-t-butoxycarbonylaminomethylmorpholine-4-sulphonyl) -phenyl]-5,7-dimethyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-phenylpiperazine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo-[5,1-f]-[1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(3-hydroxy-3-methoxymethylpyrrolidine-1-sulphonyl)-phenyl]-5,7-di-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one lactate;
- 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride;
- 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride;
- 2-[2-ethoxy-5-(4-methyl-1-amino-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-hydroxyethyl-1-amino-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- N,N-bishydroxyethylaminoethyl-4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)benzenesulphonamide;
- 2-[2-ethoxy-5-(4-dimethoxyphosphorylmethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-diethoxyphosphorylmethyl-piperidine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-hydroxy-piperidine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-{2-ethoxy-5-[4-(2-hydroxy-ethyl)-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-{2-ethoxy-5-[4-(2-hydroxy-ethyl)-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride;
- 2-{2-ethoxy-5-[4-(3-hydroxy-propyl)-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- N-allyl-4-ethoxy-N-(2-hydroxy-ethyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)benzenesulphonamide;
- N-ethyl-4-ethoxy-N-(2-hydroxy-ethyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)benzenesulphonamide;
- N,N-diethyl-4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)benzenesulphonamide;
- N-(2-methoxyethyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-benzenesulphonamide;
- N-(2-N,N-dimethylethyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-benzenesulphonamide;
- N-[3-(1-morpholino)propyl]-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-benzenesulphonamide;
- N-{3-[1-(4-methyl)piperazino]-propyl}-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-benzenesulphonamide;
- 2-{2-ethoxy-5-[4-(2-methoxy-ethyl)-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-{2-ethoxy-5-[4-(2-N,N-dimethyl-ethyl)-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-{2-ethoxy-5-[4-(3-N,N-dimethyl-propyl)-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-dioxolano-piperidine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-(5-methyl-4-furoxancarbonyl)-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-{2-ethoxy-5-[4-acetyl-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-{2-ethoxy-5-[4-formyl-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(3-butylsydnoneimine)-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 5-methyl-2-[5-(4-methyl-piperazine-1-sulphonyl)-2-propoxy-phenyl]-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 5-methyl-2-[5-(4-methyl-piperazine-1-sulphonyl)-2-propoxy-phenyl]-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride;
- 2-[5-(4-hydroxypiperidine-1-sulphonyl)-2-propoxy-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[5-(4-hydroxymethylpiperidine-1-sulphonyl)-2-propoxy-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-{5-[4-(2-hydroxyethyl)-piperazine-1-sulphonyl]-2-propoxy-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- N-(1,1-dioxotetrahydro-1Δ6-thiophen-3-yl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo-[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- N-(2-dimethylaminoethyl)-N-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- 3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-N-(3-morpholin-4-yl-propyl)-4-propoxy-benzenesulphonamide;
- N,N-bis-(2-hydroxyethyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- N-(3-hydroxybenzyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- N-ethyl-N-(2-hydroxyethyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- N-(3-ethoxypropyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f]-[1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- 2-[5-(4-hydroxypiperidine-1-sulphonyl)-2-propoxy-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-N-pyridin-4-yl-benzenesulphonamide;
- N,N-diethyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- 1-[3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonyl]-piperidine-4-carboxylic acid;
- 5-methyl-2-[5-(morpholine-4-sulphonyl)-2-propoxy-phenyl]-7-propyl-3H-imidazo-[5,1-f][1,2,4]triazin-4-one;
- N-(2-hydroxyethyl)-N-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- N-(2-hydroxyethyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-N-propyl-benzenesulphonamide;
- N-[2-(3,4-dimethoxy-phenyl)ethyl]-N-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxy-benzenesulphonamide;
- N-allyl-N-(2-hydroxyethyl)-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxybenzenesulphonamide;
- N-allyl-N-cyclopentyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxybenzenesulphonamide;
- N-allyl-N-ethyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-propoxybenzenesulphonamide;
- 2-[2-ethoxy-4-methoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-{2-ethoxy-5-[4-(2-hydroxyethyl)-piperazine-1-sulphonyl]-4-methoxy-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 4-ethoxy-N-ethyl-N-(2-hydroxyethyl)-2-methoxy-5-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonamide;
- 4-ethoxy-N-(4-ethoxyphenyl)-2-methoxy-5-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonamide;
- 4-ethoxy-N-ethyl-N-(2-hydroxy-ethyl)-3-(5-ethyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)benzenesulphonamide;
- N-(2-methoxyethyl)-3-(5-ethyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulphonamide;
- N,N-bis-(2-methoxyethyl)-3-(5-ethyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]tri-azin-2-yl)-4-ethoxybenzenesulphonamide;
- 2-[5-(4-hydroxypiperidine-1-sulphonyl)-2-ethoxyphenyl]-5-ethyl-7-propyl-3H-imidazo[5,1-f]-[1,2,4]triazin-4-one;
- 2-[5-(4-hydroxymethylpiperidine-1-sulphonyl)-2-ethoxy-phenyl]-5-ethyl-7-propyl-3H-imidazo[5,1-f](1,2,4]triazin-4-one;
- 2-{2-ethoxy-5-[4-(2-hydroxyethyl)-piperazine-1-sulphonyl]-phenyl}-5-ethyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-5-ethyl-7-propyl-3H-imidazo[5,1-f]-[1,2,4]triazin-4-one;
- 2-[2-ethoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-5-ethyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride;
- 3-(5-ethyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-N-(3-morpholin-4-yl-propyl)-4-ethoxybenzenesulphonamide;
- N-(2-hydroxyethyl)-3-(5-ethyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-N-propyl-benzenesulphonamide;
- 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazol[5,1-f][1,2,4]triazin-4-one hydrochloride trihydrate;
- 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one dihydrochloride.
- The compounds according to the invention can be prepared according to the description in WO 99/24433, reference to whose disclosure in this respect is expressly made here.
- The compounds according to the invention inhibit the c-GMP-metabolizing phosphodiesterases 5. This leads to an increase in c-GMP. The differential expression of the phosphodiesterases in various cells, tissues and organs, just like the differential subcellular location of these enzymes, make possible, in combination with the selective inhibitors according to the invention, a selective addressing of the various processes regulated by cGMP.
- Moreover, the compounds according to the invention reinforce the action of substances, such as, for example, EDRF (endothelium derived relaxing factor), ANP (atrial natriuretic peptide), of nitro vasodilators and all other substances which increase the cGMP concentration in a manner other than phosphodiesterase inhibitors.
- The compounds of the general formula (I) according to the invention are therefore suitable for the prophylaxis and/or treatment of disorders in which an increase in the cGMP concentration is beneficial, i.e. disorders which are connected with cGMP-regulated processes (in English usually simply designated as ‘cGMP-related diseases’). According to the present invention, those concerned here are cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
- Temporary or permanent damage to the eyes can result on account of constriction of a blood vessel and a defective supply of the eye with nutrients resulting therefrom. For example, this—in addition to high intraocular pressure—can be one of the causes of glaucoma (cf. e.g. Van de Voorde, J. Invest. Ophthal. & Vis. Sci. 39(9):1642-1646 (1998)). There are reports about a slowing of the progress of glaucomatous optical neuropathy in the case of systemic administration of an NO donor, which could be attributed to a dilation of the blood vessels in the eye (cf. Afshari, Invest. Opthalmol. Vis. Sci. 38(Suppl.):S277 (1997); Grunwald, British J. Ophthal. 83(2):162-167 (1999)). Inhibitors of the cGMP PDE lead—as described above—analogously to NO donors, to an increase in the cGMP level and can thus, inter alia, cause a vasodilation of the blood vessels in the eyes and thus be used for the treatment of glaucomas.
- In principle, the compounds of the formula (I), however, can also be used for the treatment of other disorders of the eye, for example for the treatment or prophylaxis of central retinal or posterior ciliary arterial occlusion, central retinal venous occlusion, optical neuropathy such as anterior ischaemic optical neuropathy and glaucomatous optical neuropathy, and of macular degeneration.
- The activity of the compounds of the formula (I) as inhibitors of the phosphodiesterases (PDEs) is described in WO 99/24433, reference to whose contents in this respect is expressly made.
- The active compounds and their physiologically acceptable salts (e.g. hydrochlorides, maleates or lactates) can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic pharmaceutically suitable vehicles or solvents. The therapeutically active compound should in each case be present here in a concentration of approximately 0.5 to 9% by weight of the total mixture, i.e. in amounts which are sufficient in order to achieve the dosage range indicated. The formulations are prepared, for example, by extending the active compounds using solvents and/or vehicles, optionally using emulsifying agents and/or dispersing agents, where, for example, if water is used as a diluent, organic solvents can optionally be used as auxiliary solvents.
- Administration is carried out in a customary manner, preferably orally, transdermally or parenterally, e.g. perlingually, buccally, intravenously, nasally, rectally or by inhalation.
- For use in man, in the case of oral administration doses of 0.001 to 50 mg/kg, preferably 0.01 mg/kg-20 mg/kg, are more usefully administered. In the case of parenteral administration, such as, for example, nasally, buccally or by inhalation via the mucous membranes, a dose of 0.001 mg/kg-0.5 mg/kg is useful.
- In spite of this, it may optionally be necessary to depart from the amounts mentioned, namely depending on the body weight or on the type of administration route, on individual behaviour towards the medicament, the manner of its formulation and the time or interval at which administration takes place. Thus in some cases it may be sufficient to manage with less than the abovementioned minimum amount, while in other cases the upper limit mentioned has to be exceeded. In the case of the administration of relatively large amounts, it may be advisable to divide these into a number of individual doses over the course of the day.
- The compounds according to the invention are also suitable for use in veterinary medicine. For applications in veterinary medicine, the compounds or their non-toxic salts are administered in a suitable formulation in agreement with the general veterinary medical practices. The veterinary surgeon can fix the type of administration and the dose according to the type of the animal to be treated.
Claims (3)
1. A method for the treatment of cardiac insufficiency, cancer, bladder disorders, or prostate hyperplasia, comprising administering to a subject in need thereof an effective amount of one or more 2-phenyl-substituted imidazotriazinones of formula (I)
in which
R1 represents methyl or ethyl,
R2 represents ethyl or propyl,
R3 and R4 are identical or different and represent a straight-chain or branched alkyl chain having up to 5 carbon atoms, which is optionally up to disubstituted identically or differently by hydroxyl or methoxy,
or
R3 and R4 together with the nitrogen atom form a piperidinyl ring, morpholinyl ring, thiomorpholinyl ring or a radical of the formula
in which
R5 denotes hydrogen, formyl, acyl or alkoxycarbonyl in each case having up to 3 carbon atoms,
or denotes straight-chain or branched alkyl having up to 3 carbon atoms, which is optionally mono- to disubstituted, identically or differently, by hydroxyl, carboxyl, straight-chain or branched alkoxy or alkoxycarbonyl in each case having up to 3 carbon atoms or by groups of the formula -(D)aNR6R7 or —P(O)(OR8)(OR9),
in which
a denotes a number 0 or 1,
D denotes a group of the formula —CO,
R6 and R7 are identical or different and denote hydrogen or methyl,
R8 and R9 are identical or different and denote hydrogen, methyl or ethyl,
or
R5 denotes cyclopentyl,
and the heterocycles mentioned under R3 and R4, formed together with the nitrogen atom, are optionally mono- to disubstituted, identically or differently, optionally also geminally, by hydroxyl, formyl, carboxyl, acyl or alkoxycarbonyl in each case having up to 3 carbon atoms or groups of the formula —P(O)(OR10)(OR11) or —(CO)bNR12R13,
in which
R10 and R11 are identical or different and denote hydrogen, methyl or ethyl,
b denotes a number 0 or 1,
and
R12 and R13 are identical or different and denote hydrogen or methyl
or the heterocycles mentioned under R3 and R4, formed together with the nitrogen atom, are optionally substituted by straight-chain or branched alkyl having up to 3 carbon atoms, which is optionally mono- to disubstituted, identically or differently, by hydroxyl, carboxyl or by a radical of the formula P(O)OR14OR5,
in which
R14 and R15 are identical or different and denote hydrogen, methyl or ethyl,
or the heterocycles mentioned under R3 and R4, formed together with the nitrogen atom, are optionally substituted by piperidinyl or pyrrolidinyl linked via N,
and
R16 represents ethoxy or propoxy,
or a salt, hydrate, or solvate thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/906,382 US20080085897A1 (en) | 2001-07-23 | 2007-10-01 | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10135815A DE10135815A1 (en) | 2001-07-23 | 2001-07-23 | Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain |
DE10135815.6 | 2001-07-23 | ||
US10/483,462 US6930108B2 (en) | 2001-07-23 | 2002-07-17 | Use of 2-alkoxyphenol-substituted imidazotriazinones |
PCT/EP2002/007959 WO2003011262A2 (en) | 2001-07-23 | 2002-07-17 | Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cgmp regulated processes |
US11/156,082 US7276504B2 (en) | 2001-07-23 | 2005-06-17 | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
US11/906,382 US20080085897A1 (en) | 2001-07-23 | 2007-10-01 | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/156,082 Continuation US7276504B2 (en) | 2001-07-23 | 2005-06-17 | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080085897A1 true US20080085897A1 (en) | 2008-04-10 |
Family
ID=7692784
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/483,462 Expired - Fee Related US6930108B2 (en) | 2001-07-23 | 2002-07-17 | Use of 2-alkoxyphenol-substituted imidazotriazinones |
US11/156,082 Expired - Fee Related US7276504B2 (en) | 2001-07-23 | 2005-06-17 | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
US11/906,382 Abandoned US20080085897A1 (en) | 2001-07-23 | 2007-10-01 | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/483,462 Expired - Fee Related US6930108B2 (en) | 2001-07-23 | 2002-07-17 | Use of 2-alkoxyphenol-substituted imidazotriazinones |
US11/156,082 Expired - Fee Related US7276504B2 (en) | 2001-07-23 | 2005-06-17 | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
Country Status (28)
Country | Link |
---|---|
US (3) | US6930108B2 (en) |
EP (2) | EP1733728A3 (en) |
JP (1) | JP2005504751A (en) |
KR (1) | KR20040032865A (en) |
CN (1) | CN1649593A (en) |
AT (1) | ATE442144T1 (en) |
AU (1) | AU2002319296B2 (en) |
BG (1) | BG108533A (en) |
BR (1) | BR0211359A (en) |
CA (1) | CA2454414A1 (en) |
CO (1) | CO5560536A2 (en) |
CZ (1) | CZ2004128A3 (en) |
DE (2) | DE10135815A1 (en) |
EC (1) | ECSP044956A (en) |
EE (1) | EE200400056A (en) |
ES (1) | ES2330418T3 (en) |
HR (1) | HRP20040065A2 (en) |
HU (1) | HUP0500734A3 (en) |
IL (1) | IL159840A0 (en) |
MA (1) | MA26128A1 (en) |
MX (1) | MXPA04000675A (en) |
NO (1) | NO20040294L (en) |
NZ (1) | NZ530703A (en) |
PL (1) | PL373392A1 (en) |
RU (1) | RU2321406C9 (en) |
SK (1) | SK442004A3 (en) |
UA (1) | UA76997C2 (en) |
WO (1) | WO2003011262A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10135815A1 (en) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain |
JP2006219374A (en) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Imidazotriazinone derivative having pde 7 inhibition |
DE102004023069A1 (en) | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | New dosage forms of the PDE 5 inhibitor vardenafil |
DE102004038328A1 (en) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | New uses of 2-phenyl-substituted imidazotriazinone derivatives |
WO2006111495A1 (en) | 2005-04-19 | 2006-10-26 | Nycomed Gmbh | Roflumilast for the treatment of pulmonary hypertension |
CN102791701B (en) * | 2009-12-30 | 2014-02-12 | 深圳信立泰药业股份有限公司 | 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase IV(DPP-IV) inhibitors |
AT512084A1 (en) * | 2011-10-20 | 2013-05-15 | Univ Wien Tech | DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
WO2018112149A1 (en) * | 2016-12-16 | 2018-06-21 | Cystic Fibrosis Foundaton Therapeutics Inc. | Bycyclic heteroaryl derivatives as cftr potentiators |
CN113461694A (en) * | 2021-08-05 | 2021-10-01 | 广东西捷药业有限公司 | Vardenafil analogue and synthetic method and application thereof |
CN113583003A (en) * | 2021-08-05 | 2021-11-02 | 广东西捷药业有限公司 | Vardenafil analogue and synthetic method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6362178B1 (en) * | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6930108B2 (en) * | 2001-07-23 | 2005-08-16 | Bayer Healthcare Ag | Use of 2-alkoxyphenol-substituted imidazotriazinones |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791025A (en) | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | HETEROCYCLIC COMPOUNDS |
GB1457873A (en) | 1973-01-04 | 1976-12-08 | Allen & Hanburys Ltd | Imidazotriazines |
DK109578A (en) * | 1977-03-25 | 1978-09-26 | Allen & Hanburys Ltd | PROCEDURE FOR MAKING HETEROCYCLIC COMPOUNDS |
US4308384A (en) | 1978-09-18 | 1981-12-29 | Glaxo Group Limited | Production of triazinones |
US4479210A (en) * | 1982-11-19 | 1984-10-23 | U.S. Philips Corporation | Record-disc player |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
ATE219765T1 (en) * | 1995-04-10 | 2002-07-15 | Fujisawa Pharmaceutical Co | INDOLE DERIVATIVES AS CGMP-PDE INHIBITORS |
WO1997024334A1 (en) * | 1995-12-28 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
DE19812462A1 (en) * | 1998-03-23 | 1999-09-30 | Bayer Ag | New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases |
BR9813540A (en) * | 1997-12-12 | 2000-10-10 | Cell Pathways Inc | Condensation products of n-benzyl-3-indenylacetamides substituted with heterocyclic aldehydes for neoplasia |
US6087368A (en) * | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
DE19827640A1 (en) | 1998-06-20 | 1999-12-23 | Bayer Ag | New imidazotriazine derivatives useful as smooth muscle relaxants for treating e.g. cardiovascular disorders, cerebrovascular disorders, or erectile dysfunction |
IL132406A0 (en) * | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
US6225315B1 (en) * | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
FR2792634B1 (en) * | 1999-04-20 | 2001-06-01 | Synthelabo | 2-ALCOXY-CYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
IL130968A (en) * | 1999-07-15 | 2002-12-01 | Shmuel Simon | Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss |
EP1218003A4 (en) * | 1999-09-13 | 2004-02-11 | David M Swope | Composition and method for decreasing neurologic symptomatology |
DE19943815A1 (en) * | 1999-09-14 | 2001-03-15 | Merck Patent Gmbh | Use of thienopyrimidines |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
US6503908B1 (en) | 1999-10-11 | 2003-01-07 | Pfizer Inc | Pharmaceutically active compounds |
ES2272297T3 (en) * | 1999-10-12 | 2007-05-01 | Lilly Icos Llc | MEDICATION INTENDED FOR THE TREATMENT OF NEUROPATHIES. |
IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
GB0008694D0 (en) * | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
DE60124085D1 (en) * | 2000-04-19 | 2006-12-07 | Lilly Icos Llc | PDE-V HEMMER FOR THE TREATMENT OF MORBUS PARKINSON |
CN1630532A (en) * | 2000-04-19 | 2005-06-22 | 约翰斯霍普金斯大学 | Methods for prevention and treatment of gastrointestinal disorders |
WO2002013798A2 (en) * | 2000-08-11 | 2002-02-21 | Pfizer Limited | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
EP1313478A2 (en) * | 2000-08-30 | 2003-05-28 | Lilly Icos LLC | Method for treatment of migraine using pde5 inhibitors |
GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
BR0206847A (en) * | 2001-02-02 | 2004-02-25 | Pfizer | Diabetes Mellitus Treatment |
DE10107639A1 (en) * | 2001-02-15 | 2002-08-22 | Bayer Ag | 2-alkoxyphenyl substituted imidazotriazinones |
PL363679A1 (en) * | 2001-05-09 | 2004-11-29 | Bayer Healthcare Ag | Novel use of 2-phenyl-substituted imidazotriazinones |
GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
CA2478145A1 (en) * | 2002-03-06 | 2003-09-12 | Cellegy Pharmaceuticals, Inc. | Formulations and methods of using nitric oxide mimetics in cancer treatment |
-
2001
- 2001-07-23 DE DE10135815A patent/DE10135815A1/en not_active Withdrawn
-
2002
- 2002-07-17 EE EEP200400056A patent/EE200400056A/en unknown
- 2002-07-17 MX MXPA04000675A patent/MXPA04000675A/en active IP Right Grant
- 2002-07-17 HU HU0500734A patent/HUP0500734A3/en unknown
- 2002-07-17 UA UA2004021279A patent/UA76997C2/en unknown
- 2002-07-17 US US10/483,462 patent/US6930108B2/en not_active Expired - Fee Related
- 2002-07-17 WO PCT/EP2002/007959 patent/WO2003011262A2/en active Application Filing
- 2002-07-17 DE DE50213840T patent/DE50213840D1/en not_active Expired - Fee Related
- 2002-07-17 NZ NZ530703A patent/NZ530703A/en unknown
- 2002-07-17 CZ CZ2004128A patent/CZ2004128A3/en unknown
- 2002-07-17 SK SK44-2004A patent/SK442004A3/en not_active Application Discontinuation
- 2002-07-17 EP EP06017257A patent/EP1733728A3/en not_active Withdrawn
- 2002-07-17 BR BR0211359-7A patent/BR0211359A/en not_active IP Right Cessation
- 2002-07-17 ES ES02748858T patent/ES2330418T3/en not_active Expired - Lifetime
- 2002-07-17 AT AT02748858T patent/ATE442144T1/en not_active IP Right Cessation
- 2002-07-17 EP EP02748858A patent/EP1474150B1/en not_active Expired - Lifetime
- 2002-07-17 CA CA002454414A patent/CA2454414A1/en not_active Abandoned
- 2002-07-17 KR KR10-2004-7001050A patent/KR20040032865A/en not_active Application Discontinuation
- 2002-07-17 AU AU2002319296A patent/AU2002319296B2/en not_active Ceased
- 2002-07-17 IL IL15984002A patent/IL159840A0/en unknown
- 2002-07-17 CN CNA028144759A patent/CN1649593A/en active Pending
- 2002-07-17 RU RU2004105265/15A patent/RU2321406C9/en not_active IP Right Cessation
- 2002-07-17 PL PL02373392A patent/PL373392A1/en not_active Application Discontinuation
- 2002-07-17 JP JP2003516493A patent/JP2005504751A/en active Pending
-
2004
- 2004-01-14 BG BG108533A patent/BG108533A/en unknown
- 2004-01-19 EC EC2004004956A patent/ECSP044956A/en unknown
- 2004-01-22 MA MA27497A patent/MA26128A1/en unknown
- 2004-01-22 HR HRP20040065 patent/HRP20040065A2/en not_active Application Discontinuation
- 2004-01-22 NO NO20040294A patent/NO20040294L/en not_active Application Discontinuation
- 2004-02-23 CO CO04015666A patent/CO5560536A2/en not_active Application Discontinuation
-
2005
- 2005-06-17 US US11/156,082 patent/US7276504B2/en not_active Expired - Fee Related
-
2007
- 2007-10-01 US US11/906,382 patent/US20080085897A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6362178B1 (en) * | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6930108B2 (en) * | 2001-07-23 | 2005-08-16 | Bayer Healthcare Ag | Use of 2-alkoxyphenol-substituted imidazotriazinones |
US7276504B2 (en) * | 2001-07-23 | 2007-10-02 | Bayer Healthcare Ag | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7276504B2 (en) | Use of 2-alkoxyphenyl-substituted imidazotriazinones | |
RU2130776C1 (en) | Pyrazolepyrimidinones for treatment of impotents | |
US11464781B2 (en) | PDE1 inhibitors for ophthalmic disorders | |
EP0918519B1 (en) | Therapeutic treatment for vegf related occular diseases | |
JP2005524626A (en) | Methods for treating eye diseases | |
US20040152700A1 (en) | Novel use of 2-phenyl-substituted imidazotriazinones | |
JP2001048788A (en) | Method and for treating disease and condition of eye composition | |
US6300328B1 (en) | Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage | |
US20060148802A1 (en) | Use of compounds that stimulate cgmp | |
CN118119390A (en) | Compositions and methods for prolonged release of clocaline therapy | |
US20080096880A1 (en) | Novel use of imidazotriazinones | |
US20230414621A1 (en) | No-pde5 inhibitor for use in treating dry age-related macular degeneration, geographic atrophy and glaucoma-associated neurodegeneration | |
US20220073503A1 (en) | Nitric oxide donor and anti-oxidant compounds | |
US20100331311A1 (en) | Galantamine as a neuroprotective drug for retinal ganglion cells | |
RU2004104337A (en) | COMPOSITIONS AND METHODS FOR INTRODUCING TUBULIN BINDING MEDICINES FOR THE TREATMENT OF EYE DISEASES | |
WO2000067740A2 (en) | Aminoguanidine for treating glaucomatous optic neuropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023769/0122 Effective date: 20081204 Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT,GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023769/0122 Effective date: 20081204 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |